The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism?

Steffens, Sabine

The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism? [electronic resource] - Current drug targets 2015 - 334-41 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review

1873-5592

10.2174/1389450115666141202113225 doi


Atherosclerosis--drug therapy
Blood Pressure
Cannabinoid Receptor Agonists--therapeutic use
Cannabinoid Receptor Antagonists--therapeutic use
Cardiovascular System--drug effects
Cholesterol--metabolism
Endocannabinoids--metabolism
Humans
Molecular Targeted Therapy
Myocardial Contraction
Protective Factors
Receptor, Cannabinoid, CB1--antagonists & inhibitors
Receptor, Cannabinoid, CB2--agonists
Risk Factors
Signal Transduction--drug effects